SURPAS通用计算器在全关节置换术中的准确性评估
本研究基于2012年ACS-NSQIP数据,评估SURPAS通用风险计算器对全关节置换术(TJA)患者30天结局的预测准确性。结果显示TJA队列的C指数均低于原开发数据集,校准差,死亡率被高估而并发症率被低估。提示通用计算器需针对特定手术验证。
要点
- SURPAS在TJA中区分度低于原开发数据集,C指数范围0.56-0.82。
- 校准不佳:各风险十分位死亡率低于预期,并发症率高于预期。
- 通用风险计算器应针对特定手术或手术组进行验证后使用。
核心结论
- SURPAS通用模型对TJA的预测准确性低于其原开发数据集所涵盖的广泛手术。
研究设计与样本
- 从2012年ACS-NSQIP中识别非急诊THA或TKA患者内部子集,应用已发表的SURPAS逻辑回归模型系数计算预测概率。
- 评估30天术后结局:死亡率、总体并发症及六个并发症聚类(肺部、感染、心脏或输血、肾脏、静脉血栓栓塞、神经)。
- 用C指数评估区分度,用Hosmer-Lemeshow 10组卡方检验和十分位图评估校准。
主要发现
- TJA的30天死亡率0.1%,低于SURPAS开发数据集的1%。
- TJA常见并发症:术中或术后输血16%,尿路感染5%,静脉血栓3%。
- 关节置换的C指数从静脉血栓栓塞0.56(95%CI 0.53-0.59,SURPAS C指数0.78)到死亡率0.82(95%CI 0.76-0.88,SURPAS C指数0.94)。
- 所有关节置换C指数估计值(包括CI)均低于原SURPAS开发研究报告值。
- 十分位图和Hosmer-Lemeshow检验提示校准差;各风险十分位观察死亡率低于预期(最低十分位:观察0.0% vs 预期0.1%;最高十分位:观察0.7% vs 预期2%;p<0.001),观察并发症率高于预期(最低十分位:观察12% vs 预期8%;最高十分位:观察32% vs 预期25%;p<0.001)。
关键数值与推荐
- TJA 30天死亡率0.1%,SURPAS开发数据集死亡率1%。
- TJA常见并发症率:输血16%,尿路感染5%,静脉血栓3%。
- C指数:静脉血栓栓塞0.56(95%CI 0.53-0.59) vs SURPAS 0.78;死亡率0.82(95%CI 0.76-0.88) vs SURPAS 0.94。
- 校准:最低风险十分位死亡率观察0.0% vs 预期0.1%,最高十分位观察0.7% vs 预期2%(p<0.001);最低十分位并发症率观察12% vs 预期8%,最高十分位观察32% vs 预期25%(p<0.001)。
临床怎么用
- SURPAS模型估计值需针对个体手术或限制性手术组(如关节置换)进行评估。
- 鉴于手术间患者人群和结局差异大,通用围手术期风险计算器可能无法为特定手术提供准确可靠结果。
- 外科医生和医疗管理者应使用针对特定手术开发和验证的风险计算器。
- 需继续评估通用风险计算器在基于结局事件率和预测变量患病率相似性的更窄手术类别中的准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical outcome prediction models are useful for many purposes, including informed consent, shared decision making, preoperative mitigation of modifiable risk, and risk-adjusted quality measures. The recently reported Surgical Risk Preoperative Assessment System (SURPAS) universal risk calculators were developed using 2005-2012 American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), and they demonstrated excellent overall and specialty-specific performance. However, surgeons must assess whether universal calculators are accurate for the small subset of procedures they perform. To our knowledge, SURPAS has not been tested in a subset of patients undergoing lower-extremity total joint arthroplasty (TJA). QUESTIONS/PURPOSES: How accurate are SURPAS models' predictions for patients undergoing TJA? METHODS: We identified an internal subset of patients undergoing non-emergency THA or TKA from the 2012 ACS-NSQIP, the most recent year of the SURPAS development dataset. To assess the accuracy of SURPAS prediction models, 30-day postoperative outcomes were defined as in the original SURPAS study: mortality, overall morbidity, and six complication clusters-pulmonary, infectious, cardiac or transfusion, renal, venous thromboembolic, and neurologic. We calculated predicted outcome probabilities by applying coefficients from the published SURPAS logistic regression models to the TJA cohort. Discrimination was assessed with C-indexes, and calibration was assessed with Hosmer-Lemeshow 10-group chi-square tests and decile plots. RESULTS: The 30-day postoperative mortality rate for TJA was 0.1%, substantially lower than the 1% mortality rate in the SURPAS development dataset. The most common postoperative complications for TJA were intraoperative or postoperative transfusion (16%), urinary tract infection (5%), and vein thrombosis (3%). The C-indexes for joint arthroplasty ranged from 0.56 for venous thromboembolism (95% CI 0.53 to 0.59 versus SURPAS C-index 0.78) to 0.82 for mortality (95% CI 0.76 to 0.88 versus SURPAS C-index 0.94). All joint arthroplasty C-index estimates, including CIs, were lower than those reported in the original SURPAS development study. Decile plots and Hosmer-Lemeshow tests indicated poor calibration. Observed mortality rates were lower than expected for patients in all risk deciles (lowest decile: no observed deaths, 0.0% versus expected 0.1%; highest decile: observed mortality 0.7% versus expected 2%; p < 0.001). Conversely, observed morbidity rates were higher than expected across all risk deciles (lowest decile: observed 12% versus expected 8%; highest decile: observed morbidity 32% versus expected 25%; p < 0.001) CONCLUSIONS: The universal SURPAS risk models have lower accuracy for TJA procedures than they do for the wider range of procedures in which the SURPAS models were originally developed. CLINICAL RELEVANCE: These results suggest that SURPAS model estimates must be evaluated for individual surgical procedures or within restricted groups of related procedures such as joint arthroplasty. Given substantial variation in patient populations and outcomes across numerous surgical procedures, universal perioperative risk calculators may not produce accurate and reliable results for specific procedures. Surgeons and healthcare administrators should use risk calculators developed and validated for specific procedures most relevant to each decision. Continued work is needed to assess the accuracy of universal risk calculators in more narrow procedural categories based on similarity of outcome event rates and prevalence of predictive variables across procedures.
引用
- Trickey AW, Ding Q, Harris AHS, et al. How Accurate Are the Surgical Risk Preoperative Assessment System (SURPAS) Universal Calculators in Total Joint Arthroplasty? Clin Orthop Relat Res. 2020. PMID: 31904684. doi:10.1097/CORR.0000000000001078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。